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Abstract
We present a mixture model-based analysis for identifying differences in the distribution of RNA
polymerase II (Pol II) in transcribed regions, measured using ChIP-seq (chromatin
immunoprecipitation following massively parallel sequencing technology). The statistical model
assumes that the number of Pol II-targeted sequences contained within each genomic region
follows a Poisson distribution. A Poisson mixture model was then developed to distinguish Pol II
binding changes in transcribed region using an empirical approach and an expectation-maximization
(EM) algorithm developed for estimation and inference. In order to achieve a global maximum in
the M-step, a particle swarm optimization (PSO) was implemented. We applied this model to Pol
II binding data generated from hormone-dependent MCF7 breast cancer cells and antiestrogen-
resistant MCF7 breast cancer cells before and after treatment with 17β-estradiol (E2). We
determined that in the hormone-dependent cells, ~9.9% (2527) genes showed significant changes
in Pol II binding after E2 treatment. However, only ~0.7% (172) genes displayed significant Pol II
binding changes in E2-treated antiestrogen-resistant cells. These results show that a Poisson mixture
model can be used to analyze ChIP-seq data.
Introduction
Massively parallel sequencing is a high-throughput tech-
nology capable of sequencing hundreds of thousands of
DNA fragments in a single experiment. Combined with
antibody-based chromatin immunoprecipitation assay
(or ChIP-seq assay), this technology has been demon-
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strated to be a comprehensive, quantitative and cost-effec-
tive approach for mapping protein-DNA interaction on a
genome-wide scale [1]. One ChIP-seq run can generate
more than 20 million sequence tags of up to 36 bps each,
which can then be definitively mapped to the human
genome.
Due to the large amount of data generated in high-
throughput sequencing experiments, innovative compu-
tational and statistical approaches are required to identify
biological signals from ChIP-seq data. To date, several
approaches have been applied to identify genomic regions
containing a high concentration of sequence hits, i.e.,
"ChIP-seq peaks" [1]. An underlying assumption of cur-
rent approaches is that DNA-binding proteins, such as
transcription factors, contain sequence-specific, DNA
binding domains that target a cluster of cis-acting DNA
elements sharing certain sequence features. While such
algorithms can identify DNA binding sites for highly spe-
cific transcription factors, current approaches are not
appropriate for identifying binding sites for the general
transcriptional machinery, such as RNA polymerase II
(Pol II), which typically does not display high sequence
specificity. In addition, as Pol II activity likely extends
beyond the promoter/transcription start site of active
genes, algorithms for assessing long-range Pol II binding
are needed. Therefore, in this study, we have proposed a
mixture model-based analysis for identifying differences
in Pol II distribution in combined 5'-end, open reading
frame (ORF), and 3'-untranscribed regions of active genes.
Our strategy is based on the underlying assumption that
the number of Pol II-target sequences follows a Poisson
distribution and can be used to identify differentially tran-
scribed genes under different experimental conditions.
Furthermore, our proposed methodology can be used for
making statistical inferences in experiments for which rep-
licates are not available.
To date statistical models for ChIP-seq data are very lim-
ited. Nevertheless, new algorithms for ChIP-seq can be
developed using existing framework for identifying differ-
entially expressed genes from microarray data. For exam-
ple, Kerr et al. [2] and Wolfinger et al. [3] employed
analysis of variance (ANOVA) models to conduct a hypo-
thetical test for different expression levels of individual
genes in multiple microarray experiments. Dudoit et al.
[4] used a t-statistic to address the problem of multiple
comparisons through permutation analysis. These
approaches yielded only p-values representing the proba-
bility of having an observed expression difference of a
given gene, if the status is assumed to be the same before
and after a treatment. However, for Pol II binding data
derived from ChIP-seq, these approaches cannot be used
to estimate the status change. A more appropriate choice
analyzing ChIP-seq Pol II binding data may be a Bayes or
an empirical Bayes approach. In this regard, Efron et al. [5]
proposed an empirical Bayes  model for calculating the
probability of a differentially expressed gene given the
observed data. As the empirical distribution for their t-like
statistic for each gene does not share variation informa-
tion, it works well only in situations involving at least a
few replicates. Newton et al. [6] proposed another empir-
ical Bayes model for cDNA microarray experiments with
only one replicate. According to their method, if a gene is
differentially expressed under two conditions, its level of
expression is independently generated from the same dis-
tribution [6]; otherwise, the level of expression is the same
between experimental and control samples. In their work,
the observational component follows a Gamma distribu-
tion with mean μg, and μg itself follows an inverse Gamma
distribution (prior component). This hierarchical model
is often referred to as the Gamma-Gamma model. Specifi-
cally, all genes share the same distribution for the within-
gene sampling errors, a crucial feature in their method, as
no replicates were available in their data example. Kend-
ziorski  et al. [7] further extended the Gamma-Gamma
model to situations where replicates were available. In
addition, they developed a log-normal model for the
observational component and a normal model for the
prior component. They demonstrated a comparable per-
formance for a lognormal-normal model and a Gamma-
Gamma model. A major advantage in the methods pro-
posed by Newton et al. [6] and Kendziorski et al. [7] is that
information sharing is a consequence of the empirical
Bayes approach. The model pools the variation informa-
tion across all genes, making it well suited for data sets
containing only a few replicates (e.g., 2 replicates), and we
have successfully utilized this model framework to test the
correlation among genome wide gene expression, DNA
methylation, and histone acetylation [8,9].
In the current paper, we propose a different model, Poisson
mixture model, within the same empirical Bayes frame-
work for identifying gene targets with differential Pol II
binding activities in breast cancer MCF7 cell line under
various conditions. ChIP-seq data processing, normaliza-
tion, and statistical methods are proposed in the method
section; analysis of ChIP-seq data from breast cancer cell
lines (MCF7 and its tamoxifen-resistant subline OHT-
MCF7) before and after treatment with 17β-estradial (E2),
are presented in the result section, with conclusions at the
end of the paper.
Methods
As described by Fan et al [10], MCF7 human breast cancer
cells (American Type Culture Collection, Manassas, VA)
and MCF7-OTH cells were cultured and treated with E2
(10-8 mol/L) for three hours. Then, cells were cross-linked
with 1% formaldehyde and chromatin immunoprecipita-
tion was done as previously described [11]. The antibod-BMC Genomics 2008, 9(Suppl 2):S23 http://www.biomedcentral.com/1471-2164/9/S2/S23
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ies against Pol II were purchased from Santa Cruz
Biotechnology (Santa Cruz, sc-899 X and sc-8005 X). After
immunoprecipitation and purification, ChIP DNA sam-
ple was run in 12% PAGE and the 100–300 bp DNA frac-
tion was excised and eluted from the gel slice. Then,
Illumina library was constructed and sequenced with Illu-
mina/Solexa Genome Analyzer.
Most DNA binding proteins, such as transcription factors,
bind to cis-acting DNA element with specific sequence fea-
tures usually described by a position weight matrix
(PWM). A hypothetical distribution of ChIP-seq-derived
DNA fragments corresponding to transcription factors
and RNA polymerase II (Pol II) is shown in Figs. 1A and
1B, respectively. For transcription factors, ChIP-seq
detects a set of fragments that cluster and center around
distinct biological binding sites, forming a "peak" around
the binding locus (Fig. 1A). In contrast, Pol II binds
throughout promoter regions, the 5'- and 3'- untranslated
regions, the open reading frame (ORF), and downstream
regions of the activated gene (Fig. 1B). Although Pol II can
form a distinct peak around the transcription start site
under certain circumstances, commonly-used peak-find-
ing algorithms are not able to identify Pol II-enriched
regions in gene transcript region derived from ChIP-seq
experiments.
A Poisson mixture model to identify transcripts with 
different Pol II binding quantity
Based on the assumption that the number of Pol II-bind-
ing fragments detected within gene transcript region,
including 5'- and 3'-untranslated regions and open read-
ing frames, follows a Poisson distribution, we developed a
mixture model to identify differences in Pol II binding
under two conditions, control vs. treatment. Denote yij as
the Pol II quantity for gene i (i = 1,..., n) under condition
j (j = 1, 2). In this application, j = 1, 2 indicates two bio-
logical conditions, MCF7 control (vehicle-treated) and
MCF7 treated (3 hour E2 treatment), respectively. Margin-
ally, yij follows a Poisson distribution,
where λij denotes the expected quantity of Pol II binding
for gene i under condition j (j = 1, 2). For the i-th gene, if
Pol II binding quantities within the gene transcript region
are statistically different between the two biological con-
ditions, yij follows marginal distributions with different
parameters λi1 and λi2; conversely, if the number of Pol II
binding does not demonstrate a significant difference, yij
follows the same distribution with a unified λ. A mixture
model is proposed to estimate the posterior probability of
differential Pol II binding quantity.
For unified Pol II binding quantity between two condi-
tions, λi1 and λi2 follow the same Gamma distribution (2).
The selection of Gamma distribution is based on two con-
siderations. Firstly, the two parameter Gamma distribu-
tion is a very flexible function which can be used to
describe a wide range of distribution shapes. Secondly, the
Gamma distribution is a conjugate distribution of Poisson
for the λ parameters. Hence, the follow-up expectation
step in an E-M algorithm has a close form solution.
y
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yij
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Schematics of ChIP-seq-derived DNA fragments targeting transcription factors and RNA polymerase II Figure 1
Schematics of ChIP-seq-derived DNA fragments targeting transcription factors and RNA polymerase II. Blue and red ellipses 
indicate transcription factors binding on specific cis-acting DNA element, and RNA polymerase II not targeting certain binding 
sites, respectively. Blue and red lines under the ellipses illustrate sheared DNA fragments bound by the DNA-binding protein 
and pulled down by the immunoprecipitation assay. Green box indicates the fragment derived by Solexa sequencing (~25–36 
bp).
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Otherwise, (λi1, λi2) are distributed independently.
Denote Zi as the Bernoulli random variable with probabil-
ity p, i.e., it is equal to 1 if (λi1, λi2) are independently dis-
tributed (and equal to 0 if not). Therefore, the joint
distribution of Pol II binding quantity is modeled by a
mixture of uniform binding events (p = 0) and differential
binding events (p = 1).
Based on equation (4), we implement E-M algorithm by
treating Zi as missing data.
The E-step of the algorithm is specified as:
In the M-step, the parameters in the Gamma distribution
(α1, β1, α2, β2) are estimated by maximizing the two like-
lihood functions in Equation 6.
In the M-step, the optimization procedure is challenging,
because searching for the optimal solutions for Gamma
parameters can be trapped into local optimum, causing
either slow convergence or failure to converge on the glo-
bal optimal solution. In order to overcome these difficul-
ties, we utilize particle swarm optimization (PSO), an
artificial intelligence approach that mimics a behavior of
swarm-forming agents, providing a good balance between
global optimum searching and computation efficiency
[12].
Because the likelihood functions of (α1, β1) and (α2, β2)
are factorized in equation 6, the PSO optimization proce-
dures are conducted independently using the following
four steps.
Step 1: 100 particles (potential solution) were initially
randomly distributed in 2-dimensional parameter spaces
(α1, β1) or (α2, β2).
Step 2: the likelihood of each of the 100 particles are cal-
culated by following Equation 6.
Step 3: the velocity vector of the particle, serving as the
guide to search for the optimal solution, was calculated
using Equation 7.
where Pglobal is the global optimal solution achieved so far;
Pk-local is the local optimal solution achieved by particle k;
and C0, C1, C2 are adjustable weight factors used to control
searching speed.
Step 4: in the solution space, all the particles are re-posi-
tioned based on their current positions and movement
velocities calculated in Equation 8.
Steps 1–4 will be iterated until further particle movement
cannot result in higher likelihood (defined in Equation
6).
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At the convergence, Zi can be interpreted as the probability
of differential Pol II binding between two conditions.
Although the model derivation is based on ChIP-seq data
from MCF7 cells before and after treatment with vehicle
or E2 for 3 hours, it can also be equally applied to OHT-
MCF7 (+/- E2 treatment). In practice, the solution of the
E-M algorithm converges in only 5 to 6 cycles.
Results and discussion
Genome-wide identification of Pol II binding in breast 
cancer cell lines
We tested our model on the Pol II binding quantity in
MCF7 and OHT-MCF7 breast cancer cell lines (+/- E2
treatment) derived from the use of ChIP-seq technology.
Among all the DNA fragments detected in each sample,
we selected only those with high sequencing and match-
ing quality that could be mapped to unique genomic
locus. This pre-filtering step sufficiently removed back-
ground detection noise, and 2.59, 2.52, 3.00, and 1.33
million reads passed the above filter in MCF7 control,
MCF7 E2-treated, OHT-MCF7 control, and OHT-MCF7
E2-treated samples, respectively. In order to compare Pol
II binding quantity within a specific genomic region
across multiple samples, the number of detected Pol II
fragments was normalized using the total number of
matched fragments in each sample, based on the assump-
tion that the total number of DNA-binding Pol II would
be similar in different cell types under different biological
conditions.
Estrogen-induced changes in Pol II binding quantity in two 
cell types
As the Pol II binding quantity in each gene transcript
region reflects the expression level of the corresponding
gene, we analyzed whole genome Pol II binding distribu-
tions for the four breast cancer cell samples. For MCF7, E2
treatment resulted in a slightly higher Pol II quantity dis-
tribution (Fig. 2, upper panels). Global gene profiles
Histogram of the number of Pol II binding fragments found within over 20,000  transcribed regions in four samples including  (A) wild type MCF7 control, (B) wild type MCF7 treated with E2, (C) OHT-resistant MCF7 control, and (D) OHT-resistant  MCF7 treated with E2 samples Figure 2
Histogram of the number of Pol II binding fragments found within over 20,000 open reading frames in four samples including 
(A) wild type MCF7 control, (B) wild type MCF7 treated with E2, (C) OHT-resistant MCF7 control, and (D) OHT-resistant 
MCF7 treated with E2 samples.
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tended to be higher after E2 treatment, as reflected by a
decrease in the number of genes showing a lower level of
expression and an increase in the more highly expressed
genes (Fig. 2). In control MCF7 samples, ~15,000 genes
contained less than 50 ChIP-seq-derived DNA fragments
in the gene transcript region (Fig. 2A), decreasing to
~13,000 after E2 treatment (Fig. 2B), a trend not observed
in OHT MCF7 cells.
This observation is consistent with the nature of the MCF7
cell line and the OHT-MCF7 subline, representing hor-
mone-dependent and -independent breast cancer, respec-
tively, and was also seen in the mean values and standard
deviations for these samples (Table 1). After normaliza-
tion, all four MCF7 cell lines had the same mean value for
Pol II quantity; however, the slight decrease in standard
deviation for Pol II quantity after E2 treatment of wild
type cells indicates that a greater number of genes were
expressed at a higher level. Furthermore, in the OHT cells,
which are less sensitive to E2 stimulation compared to the
parental MCF7 cell line [13], the standard deviation of Pol
II quantity distribution remained essentially unchanged
(Table 1).
Genome Pol II quantity changing level analysis
Because no replicates were available for the test data, a
Poisson  mixture model was used to identify estrogen-
induced differences in Pol II binding quantity in the two
cell lines. The results are shown as a scatter plot of the
(log2) number of fragments in control and E2-treated
samples (Fig. 3; each dot in the figure denotes a gene).
This figure demonstrates a clear trend that with the
increase of the number of Pol II binding quantity in the
gene transcript region, a less relative change is required for
a gene to be considered as major change (red dots, Zi ≥
0.9), or minor change (green dots, 0.1 ≤ Zi < 0.9), where
Zi is a posterior probability that the Pol II binding quan-
tity changed after E2 treatment. This result demonstrates a
critical feature of the Poisson mixture model: more weight
is given to high abundant signals, while additional penal-
ties are imposed on genes with low abundant quantities.
The motivation is that additional relative changes are
required to separate low abundant signals from back-
ground noise, because high signals are less sensitive to
background noise. Consistent with previous observations
[13], wild-type MCF7 cells have more gene targets with an
altered quantity of Pol II than OHT MCF7 cells.
Table 1: The mean value and standard deviation of Pol II 
quantity in gene transcript regions in MCF7 and OHT-resistant 
MCF7 cells before and after E2 treatment.
Wild Type OHT-resistant
Control Treatment Control Treatment
Mean Value 90.2 90.2 90.2 90.2
Standard Deviation 202.8 162.8 172.7 171.9
Scatter plot of Pol II binding quantity in control and E2 treated samples: (A) wild type MCF7 cells and (B) OHT-resistant MCF7  cells Figure 3
Scatter plot of Pol II binding quantity in control and E2 treated samples: (A) wild type MCF7 cells and (B) OHT-resistant MCF7 
cells. Blue, green, and red dots indicate genes with no change (Z < 0.1), minor change (0.1 ≤ Z < 0.9), and major change (Z ≥ 
0.9), respectively.
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Fragment distribution in the gene transcript region of two
genes falling in the "major change" catergories, PgR (pro-
gesterone receptor) and MYC, two well known ERα targets
in hormone-dependent breast cancer [14,15] are shown
in Fig. 4. Pol II binding quantity in the gene transcript
region of PgR was significantly increased by E2 in wild-
type MCF7, but no change was detected in OHT-MCF7
(Fig. 4B). Pol II binding in MYC, however, was signifi-
cantly increased in both MCF7 and OHT-MCF7 cells.
Overall, in wild type MCF7 cells, Pol II binding quantities
in the gene transcript region of 9.9% and 9.7% of the
genes were classified as major (Z ≥ 0.9) and minor (0.1 ≤
Z < 0.9) changes, respectively (Fig. 5A). These percentages,
however, dropped almost 10 fold to 0.7% and 1.2% in
OHT-resistant MCF7 cells, while 98.1% of genes had the
posterior probability of less than 0.1 (Fig. 5B). Further-
more, in wild type MCF7 cells, among the 2,527 and
2,464 genes showing major and minor changes, 68.1%
(1,721) and 71.2% (1,754) of the genes demonstrated
increased Pol II binding, respectively. In contrast, an
increase in Pol II binding was observed in only 61.6%
(106) of the major changed genes in the OHT-MCF7 cells.
Strikingly, this number decreased to 43.5% (136) in the
minor change group, while 56.5% (177) genes contain
decreased Pol II quantity in OHT-MCF7 (Table 2).
Conclusion
We report a Poisson mixture model to identify estrogen-
induced changes in Pol II binding quantity in wild type
MCF7 cells and OHT-resistant MCF7 cells. Despite having
only one replicate available, our model successfully iden-
tified genes with different Pol II binding quantities from
data derived using ChIP-seq technology. This model can
distinguish differentially expressed Pol II activities from
unchanged Pol II activities using a posterior probability
calculated through an empirical Bayes  approach. The
empirical Bayes approach utilizes a combination of E-M
and PSO algorithms for estimation and optimization in
detection of the differential Pol II binding in two biologi-
Examples of Pol II binding quantity in the open reading frame of (A) PGR, progesterone receptor and (B) MYC in all four sam- ples Figure 4
Examples of Pol II binding quantity in the open reading frame of (A) PGR, progesterone receptor and (B) MYC in all four sam-
ples.
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cal conditions. In this model, small signals require large
changes in binding quantity to reach the same level of sig-
nificance. The proposed model is unique in its ability to
handle the ChIP-seq data without replicates and thus is an
excellent tool for laboratories to evaluate preliminary
ChIP-seq results. However, it is important to point out
that despite the fact that no replicates are required to cal-
culate changing probability, the use of biological repli-
cates to capture persistent measurements in response to
certain treatments are strongly encouraged.
Competing interests
The authors declare that they have no competing interests.
Changes of Pol II binding quantity in wild type MCF7 cells and OHT-resistant MCF7 cells before and after E2 treatment Figure 5
Changes of Pol II binding quantity in wild type MCF7 cells and OHT-resistant MCF7 cells before and after E2 treatment. Per-
centage of genes with no change (Z < 0.1), minor change (0.1 ≤ Z < 0.9), and major change (Z ≥ 0.9) in (A) wild type MCF7 
cells and (B) OHT-resistant MCF7 cells. Number of genes with increased and decreased Pol II binding quantity in (C) wild type 
MCF7 cells and (D) OHT-resistant MCF7 cells. Dn = Down.
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Table 2: The gene numbers and percentage of whole genome in wild type and OHT-resistant MCF7 cells with minor change (0.1 ≤ Z < 
0.9) or major change (Z ≥ 0.9)Pol II quantity.
Wilde type MCF7 Cell Genes OHT-resistant MCF7 cell Genes
Up-regulate Dn-regulate Up-regulate Dn-regulate
Number Percent Number Percent Number Percent Number Percent
Minor change (0.1 ≤ Z < 0.9) 1754 6.9% 710 2.8% 136 0.5% 177 0.7%
Major change (Z ≥ 0.9) 1721 6.7% 806 3.2% 106 0.4% 66 0.3%
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